Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 24, 2021
Event: Disclosure of a recent ransomware incident under Item 8.01 Other Events.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The filing reports a material event (ransomware incident) rather than a change in financial performance. The Company stated that the incident had no significant impact on its business and did not cause any serious disruption to operations.
Outlook, Risks, and Management Commentary
- Incident Details: On November 24, 2021, the Company issued a press release regarding a ransomware incident.
- Operational Impact: Management confirmed the incident did not cause serious disruption to operations.
- Business Impact: The Company assessed the incident as having no significant impact on its business.
- Reference: The full text of the press release is incorporated by reference as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 24, 2021) for specific details regarding the ransomware incident.
- Verify if subsequent filings (e.g., 10-Q or 10-K) disclose any financial costs or remediation expenses related to this incident.
- Confirm the status of the Company's cybersecurity measures and any ongoing investigations.